Af­fimed lands mile­stone from Roche; Puma touts new PHII da­ta on cer­vi­cal can­cer

→ While Af­fimed $AFMD works to shake off the FDA hold on its Phase I pro­gram, the team is still mak­ing pre­clin­i­cal progress with its in­nate cell en­gager-based can­cer ther­a­pies. The Ger­man biotech said its big part­ner at Genen­tech has is­sued an un­spec­i­fied pay­ment for a pre­clin­i­cal mile­stone — hope­ful­ly the first of many in a col­lab­o­ra­tion worth up to $5 bil­lion.

→ Puma Biotech­nol­o­gy has post­ed pos­i­tive da­ta for ner­a­tin­inb from a PhII study in­volv­ing HER2-mu­tat­ed cer­vi­cal can­cer pa­tients $PBYI. Out of 11 pa­tients re­searchers count­ed “3 pa­tients with con­firmed par­tial re­spons­es and 3 pa­tients with sta­ble dis­ease that last­ed greater than 16 weeks. The me­di­an pro­gres­sion free sur­vival was 7.0 months.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER